KNSA Q2 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$4M54.8% margin

Operating Income

-$41M-526.4% margin

Net Income

-$42M-539.5% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$279M

Total Liabilities

$43M

Stockholders' Equity

$236M

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$41M	-$32M	-27.3%
Net Income	-$42M	-$37M	-10.9%